MX2016006620A - Receptores de células t humanas con alta afinidad modificados por medio de manipulación genetica. - Google Patents

Receptores de células t humanas con alta afinidad modificados por medio de manipulación genetica.

Info

Publication number
MX2016006620A
MX2016006620A MX2016006620A MX2016006620A MX2016006620A MX 2016006620 A MX2016006620 A MX 2016006620A MX 2016006620 A MX2016006620 A MX 2016006620A MX 2016006620 A MX2016006620 A MX 2016006620A MX 2016006620 A MX2016006620 A MX 2016006620A
Authority
MX
Mexico
Prior art keywords
tcrs
cell receptors
affinity human
engineered
engineered high
Prior art date
Application number
MX2016006620A
Other languages
English (en)
Other versions
MX371202B (es
Inventor
M Schmitt Thomas
D Greenberg Philip
N Smith Sheena
M Kranz David
t harris Daniel
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of MX2016006620A publication Critical patent/MX2016006620A/es
Publication of MX371202B publication Critical patent/MX371202B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan receptores de linfocitos T (TCR) que tienen la especificidad del antígeno WT1. Los TCR incluyen TCR con alta afinidad que se modificaron por ingeniería genética mediante la producción de genotecas de TCR en un formato de cadena simple, y luego mediante la selección de estabilidad y afinidad mejoradas en la superficie de la levadura (es decir, evolución dirigida). En algunas formas de realización, los TCR se pueden usar en forma soluble para la administración dirigida in vivo, o como genes introducidos en linfocitos T en una entorno adoptivo de linfocitos T.
MX2016006620A 2013-11-22 2014-11-21 Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética. MX371202B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361907887P 2013-11-22 2013-11-22
PCT/US2014/066903 WO2015077615A1 (en) 2013-11-22 2014-11-21 Engineered high-affinity human t cell receptors

Publications (2)

Publication Number Publication Date
MX2016006620A true MX2016006620A (es) 2017-05-11
MX371202B MX371202B (es) 2020-01-22

Family

ID=53180203

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016006625A MX2016006625A (es) 2013-11-22 2014-11-21 Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética.
MX2016006620A MX371202B (es) 2013-11-22 2014-11-21 Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética.
MX2021006932A MX2021006932A (es) 2013-11-22 2016-05-20 Receptores de celulas t humanas con alta afinidad modificados por medio de manipulacion genetica.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016006625A MX2016006625A (es) 2013-11-22 2014-11-21 Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021006932A MX2021006932A (es) 2013-11-22 2016-05-20 Receptores de celulas t humanas con alta afinidad modificados por medio de manipulacion genetica.

Country Status (20)

Country Link
US (4) US10344075B2 (es)
EP (2) EP3071594A4 (es)
JP (4) JP6476182B2 (es)
KR (2) KR20160085345A (es)
CN (2) CN105899530B (es)
AU (4) AU2014352826B2 (es)
BR (1) BR112016011567A2 (es)
CA (2) CA2930852C (es)
DK (1) DK3071593T3 (es)
ES (1) ES2729406T3 (es)
IL (2) IL245467B (es)
MX (3) MX2016006625A (es)
PL (1) PL3071593T3 (es)
PT (1) PT3071593T (es)
RU (2) RU2740648C2 (es)
SA (1) SA516371174B1 (es)
SG (2) SG10201804330YA (es)
TR (1) TR201908404T4 (es)
WO (2) WO2015077615A1 (es)
ZA (2) ZA201603116B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007047764A2 (en) 2005-10-17 2007-04-26 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
JP6282598B2 (ja) 2012-01-13 2018-02-21 メモリアル スローン ケタリング キャンサー センター 免疫原性ｗｔ１ペプチド及びその使用方法
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CA2898099A1 (en) 2013-01-15 2014-07-24 David A. Scheinberg Immunogenic wt-1 peptides and methods of use thereof
ES2729406T3 (es) 2013-11-22 2019-11-04 Univ Illinois Receptores de linfocitos T humanos de alta afinidad modificados
JP7142571B2 (ja) * 2015-09-22 2022-09-27 ユリウス－マクシミリアン－ウニヴェルシテート・ヴュルツブルク リンパ球における高レベル且つ安定な遺伝子移入のための方法
WO2017055635A1 (en) * 2015-10-01 2017-04-06 Ospedale San Raffaele S.R.L. Tcr and uses thereof
GB201520570D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
EP3394092A1 (en) * 2015-12-23 2018-10-31 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
CA3042890A1 (en) 2016-11-14 2018-05-17 Fred Hutchinson Cancer Research Center High affinity merkel cell polyomavirus t antigen-specific tcrs and uses thereof
EP3595708A4 (en) * 2017-03-15 2020-12-16 Fred Hutchinson Cancer Research Center HIGHLY POTENTIAL MAGE-A1 SPECIFIC TCRS AND USES
KR20200020681A (ko) * 2017-04-24 2020-02-26 오스페달레 산 라파엘 에스.알.엘. Tcr 및 펩티드
JP7181517B2 (ja) * 2018-01-23 2022-12-01 国立大学法人三重大学 Ｔ細胞レセプター
JP2021530546A (ja) * 2018-07-23 2021-11-11 マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. 同種異系の細胞療法における抗−ｃｄ１３７抗体薬物コンジュゲート（ａｄｃ）の使用
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
CN114555790A (zh) * 2019-08-20 2022-05-27 弗雷德哈钦森癌症研究中心 Wt-1特异性t细胞免疫疗法
CA3170403A1 (en) * 2020-02-12 2021-08-19 Abb Vie Inc. Bispecific binding molecules
JP2023524435A (ja) 2020-04-28 2023-06-12 アキレス セラピューティクス ユーケー リミテッド Ｔ細胞療法
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
US20240210396A1 (en) 2021-04-09 2024-06-27 Achilles Therapeutics Uk Limited Batch release assay for pharmaceutical products relating to t cell therapies
WO2022269250A1 (en) 2021-06-22 2022-12-29 Achilles Therapeutics Uk Limited A method for producing antigen-specific t cells
CA3226965A1 (en) * 2021-07-19 2023-01-26 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting fanci, rad51, and pbk antigens and methods of use

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3927193A (en) 1973-05-18 1975-12-16 Hoffmann La Roche Localization of tumors by radiolabelled antibodies
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4468457A (en) 1981-06-01 1984-08-28 David M. Goldenberg Method for producing a CSAp tryptic peptide and anti-CSAp antibodies
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4640561A (en) 1985-11-15 1987-02-03 Ford Motor Company Flexible printed circuit connector
US5059413A (en) 1988-04-18 1991-10-22 Xoma Corporation Scintigraphic monitoring of immunotoxins using radionuclides and heterobifunctional chelators
DK0486622T3 (da) 1989-08-09 1999-07-19 Rhomed Inc Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium
US5299253A (en) 1992-04-10 1994-03-29 Akzo N.V. Alignment system to overlay abdominal computer aided tomography and magnetic resonance anatomy with single photon emission tomography
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
SK17332000A3 (sk) 1998-05-19 2001-06-11 Avidex Limited Preskladaný rekombinantný t bunkový receptor-tcr, sekvencie nukleových kyselín, ktoré kódujú rekombinantné tcr reťazce rekombinantného tcr, a spôsob jeho výroby
DK1124568T3 (da) 1998-10-21 2008-01-02 Altor Bioscience Corp Polyspecifikke bindingsmolekyler og anvendelser deraf
NZ531208A (en) 2001-08-31 2005-08-26 Avidex Ltd Multivalent soluble T cell receptor (TCR) complexes
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
WO2004033685A1 (en) 2002-10-09 2004-04-22 Avidex Ltd Single chain recombinant t cell receptors
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
GB0328363D0 (en) * 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
WO2005114215A2 (en) 2004-05-19 2005-12-01 Avidex Ltd Method of improving t cell receptors
CA2566363C (en) 2004-05-19 2014-12-16 Avidex Ltd High affinity ny-eso t cell receptor
GB0524477D0 (en) 2005-11-30 2006-01-11 Avidex Ltd Isolated T cell receptors which specifically bind to vygfvracl-hla-24
GB0511124D0 (en) 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
US9281917B2 (en) 2007-01-03 2016-03-08 Nokia Technologies Oy Shared control channel structure
JP6069755B2 (ja) * 2008-11-24 2017-02-01 ヘルムホルツ・ツェントルム・ミュンヘン・ドイチェス・フォーシュンクスツェントルム・フュア・ゲズントハイト・ウント・ウンベルト・ゲーエムベーハー 高親和性ｔ細胞受容体およびその用途
WO2010075417A1 (en) * 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
WO2010089412A1 (en) 2009-02-09 2010-08-12 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
WO2011044186A1 (en) * 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
EA201390011A1 (ru) 2010-07-28 2013-07-30 Иммьюнокор Лтд. Т-клеточные рецепторы
RS56339B1 (sr) 2010-09-20 2017-12-29 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t ćelijski receptori i t ćelijski epitopi
SG11201407175RA (en) 2012-05-03 2014-12-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
WO2014191465A1 (en) * 2013-05-28 2014-12-04 Møller Niels Iversen Peptides derived from lawsonia intracellularis and their use in vaccination
PL228457B1 (pl) 2013-08-30 2018-03-30 Univ Jagiellonski Tomograf hybrydowy TOF-PET/CT
ES2729406T3 (es) 2013-11-22 2019-11-04 Univ Illinois Receptores de linfocitos T humanos de alta afinidad modificados
CA2956545A1 (en) 2014-08-04 2016-02-11 Fred Hutchinson Cancer Research Center T cell immunotherapy specific for wt-1

Also Published As

Publication number Publication date
SG10201804335QA (en) 2018-06-28
JP6476182B2 (ja) 2019-02-27
BR112016011583A2 (pt) 2017-09-26
RU2740648C2 (ru) 2021-01-19
SA516371174B1 (ar) 2019-04-14
AU2014352834B2 (en) 2019-08-29
MX2021006932A (es) 2021-07-07
IL245467A0 (en) 2016-06-30
EP3071593A4 (en) 2017-05-03
JP2017501130A (ja) 2017-01-12
CN105899530B (zh) 2020-05-08
CA2930852A1 (en) 2015-05-28
US20160280755A1 (en) 2016-09-29
KR20160085345A (ko) 2016-07-15
ES2729406T3 (es) 2019-11-04
JP2022023196A (ja) 2022-02-07
RU2016124179A (ru) 2017-12-27
AU2019272003A1 (en) 2019-12-19
US20160280756A1 (en) 2016-09-29
US10344075B2 (en) 2019-07-09
EP3071594A1 (en) 2016-09-28
ZA201603116B (en) 2018-12-19
PT3071593T (pt) 2019-06-27
SG10201804330YA (en) 2018-07-30
WO2015077615A1 (en) 2015-05-28
EP3071593B1 (en) 2019-03-13
US20220396606A1 (en) 2022-12-15
CA2930847A1 (en) 2015-05-28
CN105899530A (zh) 2016-08-24
NZ719720A (en) 2020-09-25
CA2930852C (en) 2024-01-23
US10023625B2 (en) 2018-07-17
WO2015077607A1 (en) 2015-05-28
AU2019272003B2 (en) 2021-05-06
PL3071593T3 (pl) 2019-11-29
EP3071594A4 (en) 2017-05-03
JP6970724B2 (ja) 2021-11-24
AU2021202274A1 (en) 2021-05-06
BR112016011567A2 (pt) 2017-10-24
AU2014352826B2 (en) 2019-08-01
AU2014352834A1 (en) 2016-05-26
RU2729383C2 (ru) 2020-08-06
MX2016006625A (es) 2016-12-02
NZ719707A (en) 2020-09-25
ZA201603169B (en) 2020-05-27
IL245468B (en) 2020-10-29
RU2016124163A (ru) 2017-12-27
IL245467B (en) 2020-04-30
DK3071593T3 (da) 2019-06-11
MX371202B (es) 2020-01-22
CN105873945A (zh) 2016-08-17
KR20160087866A (ko) 2016-07-22
TR201908404T4 (tr) 2019-07-22
KR102415259B1 (ko) 2022-06-30
US20190055298A1 (en) 2019-02-21
EP3071593A1 (en) 2016-09-28
JP2020007374A (ja) 2020-01-16
JP6697386B2 (ja) 2020-05-20
AU2014352826A1 (en) 2016-05-26
CN105873945B (zh) 2020-07-17
JP2017501129A (ja) 2017-01-12
IL245468A0 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
MX2016006620A (es) Receptores de células t humanas con alta afinidad modificados por medio de manipulación genetica.
CY1123142T1 (el) Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων
PH12021550307A1 (en) T Cell Receptor Constructs And Uses Thereof
MX2017007138A (es) Metodos y composiciones para terapia celular adoptiva.
MX2017000646A (es) Celulas geneticamente modificadas para terapia celular adoptiva.
MX2019000643A (es) Receptores de antigenos quimericos y metodos de uso.
MX2023004169A (es) Alteracion de la expresion genetica en celulas t modificadas con el receptor de antigeno quimerico (cart) y usos de las mismas.
PH12016500395A1 (en) Cell penetrating conjugates and methods of use thereof
MX2017004890A (es) Metodos y composiciones para la generación o el mantenimiento de células pluripotentes.
EP3656387A3 (en) Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
EP4279579A3 (en) Methods and compositions for natural killer cells
MX2023005612A (es) Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
MX2018010529A (es) Composiciones y metodos para la produccion y administracion de acido ribonucleico.
AU2015311681A8 (en) Globin gene therapy for treating hemoglobinopathies
MX2015010522A (es) Receptor de antígeno químerico y métodos para usarlo.
WO2012021632A3 (en) Generation and use of pluripotent stem cells
TN2014000438A1 (en) Anti-fcrn antibodies
AU2016335217A8 (en) Antigen receptors and uses thereof
MX2012007898A (es) Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
CY1123467T1 (el) Θεραπευτικο εμβολιο για τη θεραπεια του παιδικου διαβητη τυπου 1, εφαρμογη του κυτταροδιαχωριστη κυτταρομετριας ροης και της μεθοδου πολλαπλασιασμου των κυτταρων treg για την παραγωγη θεραπευτικου εμβολιου για τη θεραπεια του διαβητη τυπου 1
PH12017500018A1 (en) Myo-inositol and probiotics, and their use
MX2021001981A (es) Metodos para preparar un poloxamero para usar en medio de cultivo celular.
MX2014006088A (es) Biomarcadores para canceres que responden a moduladores de la actividad de hec1.
MX365656B (es) Nuevas vacunas contra multiples subtipos del virus del dengue.

Legal Events

Date Code Title Description
FG Grant or registration